SUBSCRIBE
SUBSCRIBE

Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.

With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.

For more information, please visit: www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.

  • 2025 BPTW Badge - RBG.png
  • 2024 - Best Places to Work - Badges - Brighspot Rework - Outlined - 20pt.png
211 Mt. Airy Road
Basking Ridge, NJ 07920
Tel: (908) 992-6400
Visit website
  • Featured Employer
NEWS
Job Trends
Top Life Science Companies Hiring Now in August
According to a BioSpace poll, approximately 86% of life science respondents are on the verge of job burnout. Are you one of the 86%? Does this mean you need to start looking for a new job? This is definitely one of your options. Start here to look at all of the great opportunities out there in the life science industry!
August 5, 2019
 · 
1 min read
 · 
Editorial Staff
FDA
Daiichi Sankyo’s Turalio Approved for Rare, Non-Cancerous Tumor
The approval is for only “select” patients where surgery isn’t an option. It also comes with a Boxed Warning for liver toxicity, which has been a problem in several clinical trials with the drug.
August 5, 2019
 · 
2 min read
 · 
Mark Terry
Career Advice
Top Life Science Companies Hiring Now in July
According to a BioSpace poll, over half (56%) of respondents are not happy with their current life sciences position. Are you one of the 56%? You deserve to be happy! Start working towards your happiness and check out job opportunities at these top companies!
July 1, 2019
 · 
1 min read
 · 
BioSpace Staff
BioForest
Top Life Science Companies Hiring Now in June
According to a BioSpace survey, almost 70% of respondents are likely to look for a new job in the 12 months. The question is, why? Of those planning to look for a new job, 54% said they wanted new challenges and 42% said they wanted more rewarding opportunities. How about you? Are you ready to look for a job with more challenges and rewarding opportunities?
June 3, 2019
 · 
1 min read
 · 
BioSpace Staff
Daiichi Sankyo Denies Report That It’s Selling Over-the-Counter Drug Unit
On Thursday, Nikkei Business reported that Japan’s Daiichi Sankyo was in negotiations with several companies to sell its over-the-counter drug unit. The final price, Nikkei Business suggested, would hit around $900 million.
May 24, 2019
 · 
2 min read
 · 
Mark Terry
FDA
Daiichi Sankyo Takes Two Products to FDA Advisory Panel; Gets One Yes, One No
The panel opposed approval of Daiichi Sankyo’s AML drug but supported approval for its TGCT treatment.
May 15, 2019
 · 
3 min read
 · 
Alex Keown
Pharm Country
Clinical Catch-up from Last Week: May 5-10
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
May 10, 2019
 · 
7 min read
 · 
Mark Terry
Courtesy of Roland Magnusson/Getty Images
Drug Development
AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Hits Primary Endpoint
The primary endpoint was objective response rate (ORR). Secondary objectives included duration of response, disease control rate, clinical benefit rate, progression-free survival and overall survival.
May 8, 2019
 · 
3 min read
 · 
Mark Terry
BioCapital
Top Life Science Companies Hiring Now in May
According to a recent BioSpace survey, 93% of respondents are open to a new job for the right opportunity. Are you one of the 93%? If so, keep your eyes open for those opportunities and don’t stop looking. You never know what may come your way!
April 30, 2019
 · 
1 min read
 · 
Editorial Staff
Load More
JOBS
View All Jobs at Daiichi Sankyo
IN THE PRESS
BioCapital
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2-Low Metastatic Breast Cancer with HR-Positive and HR-Negative Disease
June 5, 2022
 · 
29 min read
Pharm Country
ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease
June 5, 2022
 · 
28 min read
Pharm Country
Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic Breast or Lung Cancer
June 3, 2022
 · 
15 min read
Pharm Country
Daiichi Sankyo Showcases Bold Leadership in Oncology with Survival Improvements for Certain Patients with Cancer at ASCO and EHA
May 23, 2022
 · 
26 min read
Business
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
May 5, 2022
 · 
27 min read
Policy
ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen
May 5, 2022
 · 
26 min read
Business
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer
April 27, 2022
 · 
24 min read
Job Trends
ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Patients with HER2 Low Metastatic Breast Cancer
April 26, 2022
 · 
22 min read
Business
ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases
April 26, 2022
 · 
2 min read
Business
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
April 19, 2022
 · 
22 min read
Load More